Logo

PCSA

Processa Pharmaceuticals, Inc.

PCSA

Processa Pharmaceuticals, Inc. • NASDAQ
$0.26 ▲ 2.98% (+0.01)
Market Cap $14.67 M
52w High $1.50
52w Low $0.15
Dividend Yield 0%
P/E -0.21
Volume 404.88K
Outstanding Shares 56.64M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $3.489M ▼ $-3.437M ▲ 0% $-0.07 ▲ $-3.436M ▲
Q2-2025 $0 $3.951M ▲ $-3.934M ▼ 0% $-0.25 ▲ $-3.95M ▼
Q1-2025 $0 $2.847M ▲ $-2.834M ▼ 0% $-297.52 ▼ $-2.847M ▼
Q4-2024 $0 $2.735M ▼ $-2.729M ▲ 0% $-0.78 ▲ $-2.734M ▲
Q3-2024 $0 $3.425M $-3.385M 0% $-1.03 $-3.425M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $6.308M ▼ $7.585M ▼ $1.751M ▼ $5.834M ▼
Q2-2025 $6.937M ▲ $8.182M ▲ $2.075M ▲ $6.107M ▲
Q1-2025 $2.897M ▲ $4.81M ▲ $1.283M ▼ $3.527M ▲
Q4-2024 $1.191M ▼ $3.229M ▼ $1.533M ▲ $1.696M ▼
Q3-2024 $2.891M $4.942M $1.221M $3.721M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-3.437M ▲ $-3.484M ▼ $0 $2.856M ▼ $-628.2K ▼ $-3.484M ▼
Q2-2025 $-3.934M ▼ $-2.27M ▲ $0 $6.31M ▲ $4.04M ▲ $-2.27M ▲
Q1-2025 $-2.834M ▼ $-2.73M ▼ $0 $4.436M ▲ $1.706M ▲ $-2.73M ▼
Q4-2024 $-2.729M ▲ $-2.248M ▲ $0 ▲ $547.582K ▼ $-1.7M ▲ $-2.248M ▲
Q3-2024 $-3.385M $-3.603M $-3.244K $926.196K $-2.68M $-3.606M

Five-Year Company Overview

Income Statement

Income Statement Income statement: Processa is still a pure R&D company with essentially no product revenue over the past several years. The business runs at a consistent loss, reflecting research and overhead rather than commercial activity. Losses appear relatively small in absolute terms but persistent, and earnings per share look very negative mainly because of the tiny equity base and multiple reverse splits, not because cash losses suddenly exploded. Overall, the income statement is typical of a small clinical‑stage biotech: ongoing spending, no offsetting sales yet, and full dependence on future trial success or partnerships to eventually change that picture.

Balance Sheet

Balance Sheet Balance sheet: The company’s assets and cash have trended down to very low levels, signaling that past funding has largely been used to support operations. On the positive side, there is essentially no financial debt, so the balance sheet is not burdened by interest payments or large repayment obligations. Equity is thin, which is common for micro‑cap biotechs but means there is limited cushion against setbacks. In simple terms, the balance sheet shows a lean, largely unlevered company that will likely need additional external capital to sustain and advance its programs.

Cash Flow

Cash Flow Cash flow: Processa has been consistently burning cash from operations, with no material cash coming in from products and no significant outlays for buildings or equipment. That means almost all spending goes directly into research, clinical work, and basic corporate costs. The cash burn appears steady rather than rapidly accelerating, but with the cash balance now very low, the room to continue at the same pace without new funding looks limited. The company’s future hinges on its ability to secure capital through equity, partnerships, or milestone payments rather than internal cash generation for now.

Competitive Edge

Competitive Edge Competitive position: Processa competes in oncology and gastrointestinal diseases, both crowded and dominated by much larger players, but it focuses on improving well‑known chemotherapy agents rather than inventing entirely new drugs. This “next generation” strategy can be an advantage because regulators and doctors already understand the underlying medicines. The management team emphasizes regulatory expertise and has a history of involvement in many drug approvals, which could help them design smarter trials and work efficiently with the FDA. On the other hand, the company is very small, with only a handful of programs, so it is more exposed to setbacks in any single trial, and it must compete for attention, trial sites, and eventual market share against far better funded rivals.

Innovation and R&D

Innovation and R&D Innovation & R&D: R&D is where Processa is strongest. Its core idea is to fine‑tune how existing chemotherapies are processed in the body to boost cancer‑killing effect while reducing side effects. The lead program, NGC‑Cap, pairs a familiar chemotherapy pill with a drug that blocks a key enzyme, aiming to push more active drug to tumors and less toxic byproduct to healthy tissue. Beyond this, it is applying the same concept to other major chemotherapies and has already partnered out its gastroparesis drug, PCS12852, which could bring future milestone payments if the partner is successful. The approach is innovative but still unproven in later‑stage trials, so scientific and clinical risk remains high until more human data are available.

Summary

Summary: Processa is an early‑stage biotech with an attractive scientific story but a fragile financial base. The company has no revenue, a pattern of modest but steady losses, and a shrinking cash position, although it carries virtually no debt. Its strategy centers on upgrading existing chemotherapies and leveraging deep regulatory know‑how, which could shorten development paths if the data cooperate. Key upside drivers are future trial readouts for its lead oncology program and progress on partnered assets that might deliver non‑dilutive funding. Key risks are typical for small biotechs: clinical failure, financing needs, and intense competition from larger firms. Overall, it is a high‑risk, innovation‑driven platform still very much in the proof‑of‑concept stage, financially and scientifically.

NEWS

November 5, 2025 · 9:15 AM UTC

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025

Read more